Login to Your Account

Will Data BLOSSOM into Approval?

Lorcaserin's Data Offset Modest Efficacy; Arena Plans NDA

By Jennifer Boggs

Monday, September 21, 2009
Much-anticipated data from Arena Pharmaceuticals Inc.'s second Phase III study of lorcaserin didn't wow investors immediately, but the drug's impressive safety and tolerability profile left many analysts encouraged that it could find a place among stronger competitors in the growing obesity market. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription